Hormonal
In obese and diabetic rodent models, circulating resistin levels are elevated and positively correlated with insulin, glucose, and lipids, despite suppressed resistin mRNA expression in adipose tissue, indicating that nutritional regulation of resistin is mediated by insulin and glucose.
In obese individuals, high circulating resistin is linked to higher insulin and glucose levels, even if fat tissue gene expression is low. This suggests that managing insulin and glucose levels through diet and lifestyle may help regulate resistin, rather than focusing solely on fat mass reduction.
We show that while resistin mRNA is indeed suppressed in obese mice, the circulating resistin level is significantly elevated and positively correlated with insulin, glucose, and lipids.
Why this rating
High-quality animal studies with rigorous controls (knockout mice, clamps, RIA validation), but results are in mice, not humans.
Source
Regulation of Resistin Expression and Circulating Levels in Obesity, Diabetes, and Fasting
Michael W. Rajala et al. · Diabetes · 2004
DOI 10.2337/diabetes.53.7.1671
More from this paper
- Leptin treatment reduces serum resistin and resistin mRNA expression in obese mice, an effect that is independent of weight loss or food intake, suggesting leptin directly regulates resistin to improve insulin sensitivity.Good
- Hyperinsulinemia and hyperglycemia directly increase resistin mRNA expression and serum levels in wild-type mice, indicating that insulin and glucose are key regulators of resistin production.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →